Patent ID: 8350008

Claim:
An isolated chimeric, human or humanized antibody, or an antigen-binding fragment thereof, specifically binding to a WISP-1 polypeptide selected from the group consisting of polypeptides comprising (1) amino acid residues 23 to 367 or 1 to 367 of FIGS. 3A 3 C (SEQ ID NOS:3 and 4, respectively); (2) amino acid residues 23 to 367 or 1 to 367 of FIGS. 3A 3 C except for an isoleucine residue at position 184 rather than a valine residue (SEQ ID NOS:5 and 6, respectively); (3) amino acid residues 23 to 367 or 1 to 367 of FIGS. 3A 3 C except for a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:7 and 8, respectively); (4) amino acid residues 23 to 367 or 1 to 367 of FIGS. 3A 3 C except for an isoleucine residue at position 184 rather than a valine residue and except for a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:21 and 22, respectively); (5) the WISP-1 polypeptide encoded by the full-length coding sequence in ATCC Deposit No. 209533; (6) the WISP-1 polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 23; (7) the WISP-1 polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 24; (8) the WISP-1 polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 25; (9) the WISP-1 polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 26; (10) the WISP-1 polypeptide encoded by the nucleic acid sequence of SEQ ID. NO: 27; (11) the WISP-1 polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 28; and (12) the WISP-1 polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 29, each with or without an N-terminal methionine, and a pharmaceutically acceptable carrier.